Innovative Bispecific Nanobody Targeting FGL1 and PDCD1 for Next-Generation Cancer Immunotherapy

VHH-P556 is a cutting-edge, bispecific nanobody engineered to target both fibrinogen like 1 (FGL1) and programmed cell death 1 (PDCD1) with high precision. This fully humanized antibody is currently advancing through the Biological Testing stage and holds significant promise for the treatment of cancer. By simultaneously engaging FGL1 and PDCD1, VHH-P556 is designed to modulate key pathways in tumor immune evasion, supporting its potential efficacy in a variety of malignancies. This program leverages advanced antibody technology and is positioned at the forefront of immuno-oncology innovation.

Licensing Opportunity

VHH-P556 is available for out-licensing and collaborative development. We welcome inquiries from partners interested in advancing next-generation immunotherapies and maximizing the clinical and commercial value of this innovative bispecific nanobody.

Development Phase

Modality

VHH-P556 is a bispecific antibody constructed from two distinct polypeptide chains. The first chain incorporates variable domains targeting programmed cell death mechanisms, fused to a constant Fc domain, while the second chain is a single-domain antibody (nanobody) directed against fibrinogen like 1. The single-domain nanobody structure confers unique advantages such as small molecular size, superior tissue penetration, and enhanced stability compared to traditional antibodies. These structural features are especially beneficial in cancer therapy, enabling VHH-P556 to access challenging tumor microenvironments and maintain activity in diverse physiological conditions. Expression in ExpiCHO cells ensures robust and scalable production, supporting future clinical and commercial development.

Target

FGL1 and PDCD1 are central to immune regulation in cancer. FGL1 is a secreted protein implicated in immune escape mechanisms within the tumor microenvironment, while PDCD1 is a well-characterized immune checkpoint receptor expressed on T cells. Both FGL1 and PDCD1 contribute to tumor immune evasion by inhibiting T cell activation, allowing malignant cells to proliferate unchecked. FGL1 is predominantly secreted by liver and tumor cells, whereas PDCD1 is mainly found on the surface of activated lymphocytes. Inhibiting the FGL1 and PDCD1 pathways has emerged as a compelling strategy to reactivate anti-tumor immunity. The dual-targeting capability of VHH-P556 against FGL1 and PDCD1 represents a significant strategic opportunity, potentially overcoming resistance seen with monotherapies and establishing a robust foundation for cancer immunotherapy innovation.

Mechanism of Action

VHH-P556 acts by dual inhibition of immune checkpoints FGL1 and PDCD1. Through selective binding to FGL1, it interferes with ligand-mediated immune suppression in the tumor environment; by antagonizing PDCD1, it prevents inhibitory signaling on T cells, thereby enhancing anti-tumor immune responses. Together, this dual blockade disrupts synergistic immune escape pathways, potentially restoring effective T cell activity against cancer cells. The nanobody platform facilitates the generation of bispecifics and supports modular design, enabling future adaptations such as antibody-drug conjugates or multi-specific formats tailored to distinct oncological needs. This unique mechanism positions VHH-P556 as a next-generation immune checkpoint inhibitor with broad therapeutic potential.

Cancer

Cancer remains one of the most significant global health challenges. It encompasses a diverse group of diseases characterized by uncontrolled cellular growth and evasion of immune surveillance. The global cancer burden continues to rise, with millions of new cases diagnosed annually. Standard-of-care treatments include surgery, radiation therapy, chemotherapy, and targeted molecular therapies, as well as immune checkpoint inhibitors. However, limited efficacy, safety concerns, and the development of resistance highlight the need for novel therapeutic strategies. Immune evasion by tumors via mechanisms such as FGL1 and PDCD1 signaling represents a critical challenge in current oncology practice. VHH-P556, by targeting both FGL1 and PDCD1, offers the potential to overcome key resistance pathways and address the unmet medical need for more durable and effective cancer immunotherapies.